Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors for Chronic Active Epstein-Barr Virus Infection and Epstein-Barr Virus Associated Hemophagocytic Lymphohistiocytosis

NCT05841342 is registered in ClinicalTrials.gov with Beijing Friendship Hospital as lead sponsor.

NCT NCT05841342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05841342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors for Chronic Active Epstein-Barr Virus Infection and Epstein-Barr Virus Associated Hemophagocytic Lymphohistiocytosis
Lead sponsor
Beijing Friendship Hospital
Phase
Observational
Overall status
Unknown status
Start date
October 1, 2022
Completion date
June 30, 2024
Enrollment
128 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic active epstein-barr virus infection, secondary hemophagocytic lymphohistiocytosis